We help Support at Home-approved families find care.
Aged Care Home
Support at Home
Retirement Living
Finance & Placement Advice
Healthcare Equipment
Mobility and Equipment
Patient care equipment
Skin and wound Care
Safety and Security
Assessments
Assistive Technology
End of Life
Financial Services
Funerals
Placement Consultants
Advocacy
No results found
No results found
No results found
Advanced Filters
Distance (proximity)
Price Range
RAD (Refundable Accommodation Deposit) is a lump-sum payment for aged care homes. It is fully refundable when the resident leaves, as long as there are no outstanding fees.
Min RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Maximum RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Facility size
Based on how many beds the facilty has.
Any
Small
Medium
Large
Service Delivery
Services offered at a location or in a region
Any
On Site
Service Region
Features
Single rooms with ensuites
Respite beds
Extra service beds
Secure dementia beds
24/7 Registered nursing
Full or Partially government funded
Couples accommodation
Facility has pets
Non-dedicated respite
Palliative care
Partner considered without ACAT
Secure garden
Transition care
Cafe/Kiosk
Chapel/Church
Hairdressing Salon
Facility Owned Transport
Single Rooms
Rooms with ensuites
Registered nursing
Non secure dementia care
Diversional therapy
Medication supervision
Respite care
Secure access
Small pets considered

Herb proven to help Alzheimer’s patients

Posted
by DPS

A large medical study in Europe has found that a patented Ginkgo biloba leaf extract is of significant benefit to Alzheimer’s disease patients.

The study was published in Arzneimittel-Forschung (Drug Research) and involved 395 outpatients who had mild to moderate dementia with neuropsychiatric features, such as depressed mood, anxiety, irritability and aggression.

The Ginkgo biloba extract used in the study was EGb 761, which is available over the counter in Australia under the name Tebonin. During the 22-week trial subjects were given either a placebo, or 240mg per day of EGb 761.
.
The patients treated with EGb 761 showed improvement throughout the study with a highly significant advantage of 4.5 points in the SKT compared to those who received a placebo. Similar improvements were found in all other applied tests. A 35% decrease in distress was observed in caregivers of the active treatment group.

The authors of the paper said they believe that this may reflect both the patient’s improvement in behavioural and psychiatric symptoms as well as the reduction in dependency with respect to activities of daily living.

Read next

Sign up or log in with your phone number
Phone
Enter your phone number to receive a verification notification
Aged Care Guide is endorsed by
COTA logo
ACIA logo